NCT06556563: An ongoing trial by NovoCure GmbH
This trial is ongoing. It must report results 3 years, 11 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06556563 |
|---|---|
| Title | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Optune® (TTFields, 200 kHz) Concomitant With Maintenance Temozolomide and Pembrolizumab Versus Optune® Concomitant With Maintenance Temozolomide and Placebo for the Treatment of Newly Diagnosed Glioblastoma (EF-41/KEYNOTE D58). |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Feb. 3, 2025 |
| Completion date | April 30, 2029 |
| Required reporting date | April 30, 2030, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | May 15, 2026 |
| Days late | None |